Morgan Stanley Issues Positive Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price

Denali Therapeutics (NASDAQ:DNLI) had its price target boosted by analysts at Morgan Stanley from $40.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Morgan Stanley’s price target would suggest a potential upside of 108.14% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group restated a “buy” rating and set a $40.00 target price on shares of Denali Therapeutics in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Wednesday, January 21st. HC Wainwright lifted their price target on Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Finally, The Goldman Sachs Group upped their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Price Performance

DNLI stock traded down $2.29 during mid-day trading on Thursday, reaching $20.18. 1,983,249 shares of the company traded hands, compared to its average volume of 1,747,152. The company has a fifty day moving average price of $20.41 and a 200-day moving average price of $17.80. Denali Therapeutics has a 52-week low of $10.57 and a 52-week high of $23.77. The company has a market capitalization of $3.20 billion, a P/E ratio of -6.77 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the previous year, the company earned ($0.67) earnings per share. As a group, analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 35,198 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alexander O. Schuth sold 17,218 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider owned 282,828 shares in the company, valued at approximately $4,666,662. The trade was a 5.74% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DNLI. Headlands Technologies LLC bought a new position in Denali Therapeutics in the 2nd quarter worth $26,000. Johnson Financial Group Inc. bought a new position in Denali Therapeutics in the third quarter worth about $29,000. State of Wyoming purchased a new stake in Denali Therapeutics in the second quarter worth about $29,000. Aster Capital Management DIFC Ltd purchased a new stake in Denali Therapeutics in the fourth quarter worth about $57,000. Finally, Quarry LP bought a new stake in Denali Therapeutics during the 3rd quarter valued at approximately $64,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH — first FDA‑approved, brain‑penetrant enzyme replacement therapy for Hunter syndrome; includes a Rare Pediatric Disease Priority Review Voucher and supports Denali’s TransportVehicle™ platform. GlobeNewswire: FDA Approval
• Positive Sentiment: Goldman Sachs raised its price target to $40 and reiterated a Buy — represents sizable upside vs. current levels and signals institutional conviction. Benzinga: Goldman Sachs PT Raise
• Positive Sentiment: Stifel Nicolaus raised its target to $41 and moved to Buy — another high target lift adding upward analyst momentum. Benzinga: Stifel PT Raise
• Positive Sentiment: HC Wainwright bumped its target to $42 (Buy) and BTIG raised to $38 (Buy); Robert W. Baird raised to $32 (Outperform) — broad analyst upgrades today increase headline upside consensus. Benzinga: Analyst Raises TickerReport: BTIG Raise
• Neutral Sentiment: Denali is hosting a conference call/webcast today at 12:30 PM ET to discuss the FDA approval and launch plans — investors should listen for commercialization cadence, launch timing, pricing/reimbursement plans and supply capacity. Investor Webcast
• Neutral Sentiment: Short‑interest data reported in public feeds is effectively zero/ambiguous for late March — no clear short squeeze signal from the filings. (Reports appear to show 0 shares short, which is likely a reporting artifact.)
• Negative Sentiment: Accelerated approval is based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS results — this creates regulatory and commercialization execution risk. GlobeNewswire: Approval Details & COMPASS
• Negative Sentiment: Safety and tolerability issues — infusion‑related reactions, risk of hypersensitivity/anaphylaxis and other adverse events noted in prescribing information — could affect uptake and reimbursement. GlobeNewswire: Safety Info
• Negative Sentiment: Insider selling disclosed in recent summaries (executive sales cited) and mixed institutional moves are potential near‑term selling pressure factors. Quiver: Insider & Institutional Activity

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.